Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis

Human Molecular Genetics

Volumn 10, Issue 9, 2001, Pages 919-926

  Tanaka, Yuji ^a   Engelender, Simone ^b   Igarashi, Shuichi ^a   Rao, Raghuram K ^a   Wanner, Tracy ^a   Tanzi, Rudolph E ^c   Sawa, Akira ^a   Dawson, Valina L ^a   Dawson, Ted M ^a   Ross, Christopher A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CASPASE 3; CASPASE 9; CYCLOSPORIN A; DOXYCYCLINE; MUTANT PROTEIN; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE REPRESSION; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT;

ACETYLCYSTEINE; ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASE 9; CASPASES; CYCLOSPORINE; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; GENE EXPRESSION REGULATION; IMMUNOENZYME TECHNIQUES; MEMBRANE POTENTIALS; MITOCHONDRIA; MULTIENZYME COMPLEXES; MUTATION; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PC12 CELLS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; SYNUCLEINS; TETRACYCLINE; TRANSFECTION;

EID: 0035870881     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Neuropathology of Parkinson's disease
2. Genetic classification of primary neurodegenerative disease
3. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
4. Etiology and pathogenesis of Parkinson's disease
5. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
6. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
7. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
8. Alpha-synuclein in Lewy bodies
9. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies
10. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
11. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders
12. A Drosophila model of Parkinson's disease
13. Neuropathology in mice expressing human alpha-synuclein
14. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain
15. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
16. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
17. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1
18. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity
19. The ubiquitin pathway in Parkinson's disease
20. Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases
21. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family
22. Mitochondrial dysfunction in Parkinson's disease
23. Mitochondria in the etiology and pathogenesis of Parkinson's disease
24. Mitochondrial control of cell death
25. Oxidative stress and genetics in the pathogenesis of Parkinson's disease
26. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
27. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
28. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
29. Alpha-synuclein promotes mitochondrial deficit and oxidative stress
30. Relationship between dopamine content and its secretion in PC12 cells as a function of cell growth
31. Lactacystin, proteasome function, and cell fate
32. The mitochondrial death/life regulator in apoptosis and necrosis
33. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization
34. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel
35. Mitochondrial permeability transition is a central coordinating event of apoptosis
36. Mitochondria and apoptosis
37. Rat alpha-synuclein interacts with tat binding protein 1, a component of the 26S proteasomal complex
38. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice
39. Proteasomal function is impaired in substantia nigra in Parkinson's disease
40. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity
41. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
42. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
43. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway
44. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
45. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
46. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
47. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9
48. Apoptosis by death factor
49. An induced proximity model for caspase-8 activation
50. Autoproteolytic activation of pro-caspases by oligomerization
51. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids
52. Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations
53. Interaction of Alzheimer's presenilin-1 and presenilin-2 with Bcl-X(L). A potential role in modulating the threshold of cell death
54. Mitochondrial dysfunction in neurodegeneration
55. Histochemical detection of apoptosis in Parkinson's disease
56. Prevention of dopamine-induced cell death by thiol antioxidants: Possible implications for treatment of Parkinson's disease
57. Nigrostriatal neuronal death in Parkinson's disease-a passive or an active genetically-controlled process?
58. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons
59. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining
60. +-induced apoptosis in human SH-SY5Y neuroblastoma cells
61. α-Synuclein shares physical and functional homology with 14-3-3 proteins
62. The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity
63. Dopamine induces proteasome inhibition in neural PC12 cell line
64. Glutamate-induced neuronal death: A succession of necrosis or apoptosis depending on mitochondrial function